Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P51532 (
transcriptional activator
)
6,546
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tumor suppressor protein
p53 is a potent
transcriptional activator
and regulates cell growth negatively. To characterize the transcriptional activation domain (TAD) of p53, various point mutants were constructed in the context of Gal4 DNA binding domain and tested for their transactivation ability. Our results demonstrated that the positionally conserved hydrophobic residues shared with herpes simplex virus VP16 and other transactivators are essential for transactivation. Also, the negatively charged residues and proline residues are necessary for full activity, but not essential for the activity of p53 TAD. Deletion analyses showed that p53 TAD can be divided into two subdomains, amino acids 1-40 and 43-73. An in vitro glutathione S-transferase pull-down assay establishes a linear correlation between p53 TAD-mediated transactivation in vivo and the binding activity of p53 TAD to TATA-binding protein (TBP) in vitro. Mutations that diminish the transactivation ability of Gal4-p53 TAD also impair the binding activity to TBP severely. Our results suggest that at least TBP is a direct target for p53 TAD and that the binding strength of TAD to TBP (TFIID) is an important parameter controlling activity of p53 TAD. In addition, circular dichroism spectroscopy has shown that p53 TAD peptide lacks any regular secondary structure in solution and that there is no significant difference between the spectra of the wild type TAD and that of the transactivation deficient mutant type.
...
PMID:Transactivation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATA-binding protein. 755 31
Tumor suppressor protein
p53 binds to DNA in a sequence-specific manner and activates transcription from promoters near its binding site. It is also known to repress promoters lacking the p53-binding site. In this study, we demonstrate that p53 can act as a
transcriptional activator
or repressor in vivo using the same reporter with the DNA-binding site CON and these effects depend on the amount of p53 expressed. Both in Saos2 and Cos7 cells, lower concentrations of p53 lead to activation and higher concentrations lead to repression of the model promoter containing the consensus p53-binding site CON. The N-terminal part of p53 is necessary for the transcriptional activation. It is not needed, however, for the repression of the same promoter, indicating that different domains of p53 are involved in activation and repression.
...
PMID:Protein p53 modulates transcription from a promoter containing its binding site in a concentration-dependent manner. 857 41